Biotechnological engineering of heparin/heparan sulphate: A novel area of multi-target drug discovery

Current Pharmaceutical Design

Volumn 11, Issue 19, 2005, Pages 2489-2499

  Rusnati, Marco ^b   Oreste, Pasqua ^a   Zoppetti, Giorgio ^a   Presta, Marco ^b  

^a Glycores 2000 Srl   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

AIDS; Angiogenesis; Coagulation; Endothelium; FGF; Heparin; Tumour

Indexed keywords

ANTICOAGULANT AGENT; BACTERIAL POLYSACCHARIDE; BEVACIZUMAB; CYTOKINE; DEXTRAN SULFATE; DISACCHARIDE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 8; FIBROBLAST GROWTH FACTOR RECEPTOR; GLUCOSAMINE; GLUCURONIC ACID; GLYCOPROTEIN GP 120; GLYCOSAMINOGLYCAN; GLYCOSAMINOGLYCAN POLYSULFATE; GROWTH FACTOR; HEPARAN SULFATE; HEPARIN; HEPARIN DERIVATIVE; IDURONIC ACID; LOW MOLECULAR WEIGHT HEPARIN; PENTOSAN POLYSULFATE; POLYPEPTIDE; SEMAXANIB; SULFONIC ACID DERIVATIVE; SURAMIN; TRANSACTIVATOR PROTEIN; VIRUS PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIANGIOGENIC ACTIVITY; ANTICOAGULATION; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; BIOMEDICAL ENGINEERING; BIOTECHNOLOGICAL PROCEDURES; BLEEDING DISORDER; BLOOD CLOTTING DISORDER; CHEMICAL MODIFICATION; CLINICAL TRIAL; DATA ANALYSIS; DERIVATIZATION; DRUG ACETYLATION; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SULFATION; DRUG SYNTHESIS; DRUG TARGETING; ENZYME MODIFICATION; ESCHERICHIA COLI; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MEDICAL LITERATURE; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; REVIEW; THROMBOSIS; VIRUS INFECTION;

ANIMALS; ANTICOAGULANTS; HEPARIN; HEPARITIN SULFATE; HUMANS; NEOPLASMS; POLYSACCHARIDES, BACTERIAL; TECHNOLOGY, PHARMACEUTICAL; VENOUS THROMBOSIS;

EID: 21044433780     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612054367553     Document Type: Review

References (93)

1. Conrad HE. Heparin binding proteins, Academic Press: New York 1998.
2. Bendetowicz AV, Beguin S, Captain H, Hemker HC. Pharmacokinetics and pharmacodynamics of a low molecular weight heparin (enoxaparin) after subcutaneous injection, comparison with unfractionated heparin--a three way cross over study in human volunteers. Thromb Haemost 1994; 71: 305-13.
3. Linhardt RJ, Claude S. Hudson Award address in carbohydrate chemistry. Heparin: structure and activity. J Med Chem 2003; 46: 2551-64.
4. Lindahl U, Lidholt K, Spillmann D, Kjellen L. More to "heparin" than anticoagulation. Thromb Res 1994; 75: 1-32.
5. Vann WF, Schmidt MA, Jann B, Jann K. The structure of the capsular polysaccharide (K5 antigen) of urinary-tract-infective Escherichia coli 010:K5:H4. A polymer similar to desulfo-heparin. Eur J Biochem 1981; 116: 359-64.
6. Sugahara K, Kitagawa H. Recent advances in the study of the biosynthesis and functions of sulphated glycosaminoglycans. Curr Opin Struct Biol 2000; 10: 518-27.
7. Casu B, Lindahl U. Structure and biological interactions of heparin and heparan sulphate. Adv Carbohydr Chem Biochem 2001; 57: 159-206.
8. Petitou M, Casu B, Lindahl U. 1976-1983, a critical period in the history of heparin: the discovery of the antithrombin binding site. Biochimie 2003; 85: 83-9.
9. Esko JD, Lindahl U. Molecular diversity of heparan sulphate. J Clin Invest 2001; 108: 169-73.
10. Casu B, Grazioli G, Razi N, Guerrini M, Naggi A, Torri G, et al. Heparin-like compounds prepared by chemical modification of capsular polysaccharide from E. coli K5. Carbohydr Res 1994; 263: 271-84.
11. Kusche M, Hannesson HH, Lindahl U. Biosynthesis of heparin. Use of Escherichia coli K5 capsular polysaccharide as a model substrate in enzymic polymer-modification reactions. Biochem J 1991; 275 (Pt 1): 151-8.
12. Leali D, Belleri M, Urbinati C, Coltrini D, Oreste P, Zoppetti G, et al. Fibroblast growth factor-2 antagonist activity and angiostatic capacity of sulphated Escherichia coli K5 polysaccharide derivatives. J Biol Chem 2001; 276: 37900-8.
13. Vicenzi E, Gatti A, Ghezzi S, Oreste P, Zoppetti G, Poli G. Broad spectrum inhibition of HIV-1 infection by sulphated K5 Escherichia coli polysaccharicle derivatives. Aids 2003; 17: 177-81.
14. Casu B, Grazioli G, Hannesson H, Jan B, Jann K, Lindahl U, et al. Biological active, heparan sulphate-like species by combined chemical and enzymic modification of the Escherichia coli polysaccharide K5. Carbohydr Lett 1994; 1: 107-14.
15. Oreste P, Zoppetti G: U.S. patent application no US 2002 062019, 2002.
16. Naggi A, Torri G, Casu B, Oreste P, Zoppetti G, Li JP, et al. Toward a biotechnological heparin through combined chemical and enzymatic modification of the Escherichia coli K5 polysaccharide. Semin Thromb Hemost 2001; 27: 437-43.
17. Razi N, Feyzi E, Bjork I, Naggi A, Casu B, Lindahl U. Structural and functional properties of heparin analogues obtained by chemical sulphation of Escherichia coli K5 capsular polysaccharide. Biochem J 1995; 309 (Pt 2): 465-72.
18. Uchiyama H, Nagasawa K. Changes in the structure and biological property of N----O sulphate-transferred, N-resulphated heparin. J Biol Chem 1991; 266: 6756-60.
19. Lebeau B, Chastang C, Brechot JM, Capron F, Dautzenberg B, Delaisements C, et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. Cancer 1994; 74: 38-45.
20. von Tempelhoff GF, Heilmann L. Antithrombotic therapy in gynecologic surgery and gynecologic oncology. Hematol Oncol Clin North Am 2000; 14: 1151-69, ix.
21. Zacharski LR, Ornstein DL, Mamourian AC. Low-molecular-weight heparin and cancer. Semin Thromb Hemost 2000; 26 Suppl 1: 69-77.
22. Engelberg H. Actions of heparin that may effect the malignant process. Cancer 1999; 85: 257-72.
23. Klint P, Claesson-Welsh L. Signal transduction by fibroblast growth factor receptors. Front Biosci 1999; 4: D165-D77.
24. Schlessinger J, Lax I, Lemmon M. Regulation of growth factor activation by proteoglycans: what is the role of the low affinity receptors? Cell 1995; 83: 357-60.
25. Yayon A, Klagsbrun M, Esko JD, Leder P, Ornitz DM. Cell surface, lieparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 1991; 64: 841-8.
26. Guimond S, Maccarana M, Olwin BB, Lindahl U, Rapraeger AC. Activating and inhibitory heparin sequences for FGF-2 (basic FGF) Distinct requirements for FGF-1, FGF-2, and FGF-4. J Biol Chem 1993; 268: 23906-14.
27. Rusnati M, Coltrini D, Caccia P, Dell'Era P, Zoppetti G, Oreste P, et al. Distinct role of 2-O-, N-, and 6-O-sulphate groups of heparin in the formation of the ternary complex with basic fibroblast growth factor and soluble FGF receptor-1. Biochem Biophys Res Commun 1994; 203: 450-8.
28. Ishihara M, Tyrrell DJ, Stauber GB, Brown S, Cousens LS, Stack RJ. Preparation of affinity-fractionated, heparin-derived oligosaccharides and their effects on selected biological activities mediated by basic fibroblast growth factor. J Biol Chem 1993; 268: 4675-83.
29. Kouhara H, Koga M, Kasayama S, Tanaka A, Kishimoto T, Sato B. Transforming activity of a newly cloned androgen-induced growth factor. Oncogene 1994; 9: 455-62.
30. Marsh SK, Barisal GS, Zammit C, Barnard R, Coope R, Roberts-Clarke D, et al. Increased expression of fibroblast growth factor 8 in human breast cancer. Oncogene 1999; 18: 1053-60.
31. Dorkin TJ, Robinson MC, Marsh C, Bjartell A, Neal DE, Leung HY. FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease. Oncogene 1999; 18: 2755-61.
32. Ruohola JK, Valve EM, Vainikka S, Alitalo K, Harkonen PL. Androgen and fibroblast growth factor (FGF) regulation of FGF receptors in S115 mouse mammary tumour cells. Endocrinology 1995; 136: 2179-88.
33. Borgenstrom M, Jalkanen M, Salmivirta M. Sulphated derivatives of Escherichia coli K5 polysaccharides as modulators of fibroblast growth factor signaling. J Biol Chem 2003; 278: 49882-9.
34. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-57.
35. Keshet E, Ben-Sasson SA. Anticancer drug targets: approaching angiogenesis. J Clin Invest 1999; 104: 1497-501.
36. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
37. Presta M, Moscatelli D, Joseph-Silverstein J, Rifkin DB. Purification from a human hepatoma cell line of a basic fibroblast growth factor-like molecule that stimulates capillary endothelial cell plasminogen activator production, DNA synthesis, and migration. Mol Cell Biol 1986; 6: 4060-6.
38. Gerwins P, Skoldenberg E, Claesson-Welsh L. Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis. Crit Rev Oncol Hematol 2000; 34: 185-94.
39. Yamanaka Y, Friess H, Buehler M, Beger HG, Uchida E, Onda M, et al. Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumour stage. Cancer Res 1993; 53: 5289-96.
40. Takahashi Y, Ellis LM, Wilson MR, Bucana CD, Kitadai Y, Fidler IJ. Progressive upregulation of metastasis-related genes in human colon cancer cells implanted into the cecum of nude mice. Oncol Res 1996; 8: 163-9.
41. Slaton JW, Inoue K, Perrotte P, El-Naggar AK, Swanson DA, Fidler IJ, et al. Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. Am J Pathol 2001; 158: 735-43.
42. Chang E, Boyd A, Nelson CC, Crowley D, Law T, Keough KM, et al. Successful treatment of infantile hemangiomas with interferon-alpha-2b. J Pediatr Hematol Oncol 1997; 19: 237-44.
43. Presta M, Leali D, Stabile H, Ronca R, Camozzi M, Coco L, et al. Heparin derivatives as angiogenesis inhibitors. Curr Pharm Des 2003; 9: 553-66.
44. Rusnati M, Presta M. Interaction of angiogenic basic fibroblast growth factor with endothelial cell heparan sulphate proteoglycans. Biological implications in neovascularisation. Int J Clin Lab Res 1996; 26: 15-23.
45. Lundin L, Larsson H, Kreuger J, Kanda S, Lindahl U, Salmivirta M, et al. Selectively desulphated heparin inhibits fibroblast growth factor- induced mitogenicity and angiogenesis. J.Biol.Chem. 2000; 275: 24653-60.
46. Pesenti E, Sola F, Mongelli N, Grandi M, Spreafico F. Suramin prevents neovascularisation and tumour growth through blocking of basic fibroblast growth factor activity. British Journal of Cancer 1992; 66: 367-72.
47. Casu B, Guerrini M, Naggi A, Perez M, Torri G, Ribatti D, et al. Short heparin sequences spaced by glycol-split uronate residues are antagonists of fibroblast growth factor 2 and angiogenesis inhibitors. Biochemistry 2002; 41: 10519-28.
48. Firsching A, Nickel P, Mora P, Allolio B. Antiproliferative and angiostatic activity of suramin analogues. Cancer Res. 1995; 55: 4957-61.
49. Zugmaier G, Lippman ME, Wellstein A. Inhibition by pentosan polysulphate (PPS) of heparin-binding growth factors released from tumour cells and blockage by PPS of tumour growth in animals. J Natl Cancer Inst 1992; 84: 1716-24.
50. Liekens S, Leali D, Neyts J, Esnouf R, Rusnati M, Dell'Era P, et al. Modulation of fibroblast growth factor-2 receptor binding, signaling, and mitogenic activity by heparin-mimicking polysulfonated compounds. Molecular Pharmacology 1999; 56: 204-13.
51. Daly ME, Makris A, Reed M, Lewis CE. Hemostatic regulators of tumour angiogenesis: a source of antiangiogenic agents for cancer treatment? J Natl Cancer Inst 2003; 95: 1660-73.
52. Poggi A, Rossi C, Casella N, Bruno C, Sturiale L, Dossi C, et al. Inhibition of B16-BL6 melanoma lung colonies by semisynthetic sulfaminoheparosan sulphates from E. coli K5 polysaccharide. Semin Thromb Hemost 2002; 28: 383-92.
53. Smorenburg SM, Van Noorden CJ. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev 2001; 53: 93-105.
54. Varki A, Varki NM. P-selectin, carcinoma metastasis and heparin: novel mechanistic connections with therapeutic implications. Braz J Med Biol Res 2001; 34: 711-7.
55. Vlodavsky I, Mohsen M, Lider O, Svahn CM, Ekre HP, Vigoda M, et al. Inhibition of tumour metastasis by heparanase inhibiting species of heparin. Invasion Metastasis 1994; 14: 290-302.
56. Vlodavsky I, Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 2001; 108: 341-7.
57. Moore JP, Stevenson M. New targets for inhibitors of HIV-1 replication. Nat Rev Mol Cell Biol 2000; 1: 40-9.
58. Bobardt MD, Saphire AC, Hung HC, Yu X, Van der Schueren B, Zhang Z, et al. Syndecan captures, protects, and transmits HIV to T lymphocytes. Immunity 2003; 18: 27-39.
59. Rider CC. The potential for heparin and its derivatives in the therapy and prevention of HIV-1 infection. Glycoconj J 1997; 14: 639-42.
60. De Clercq E. Potential drugs for the treatment of AIDS. J Antimicrob Chemother 1989; 23 Suppl A: 35-46.
61. Witvrouw M, Desmyter J, De Clercq E. Antivial portrait series: 4. polysulphates as inhibitors of HIV and other enveloped viruses. Antivir Chem Chemother 1994; 5: 345-59.
62. Moulard M, Lortat-Jacob H, Mondor I, Roca G, Wyatt R, Sodroski J, et al. Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J Virol 2000; 74: 1948-60.
63. Clapham PR, McKnight A. HIV-1 receptors and cell tropism. Br Med Bull 2001; 58: 43-59.
64. Abrams DI, Kuno S, Wong R, Jeffords K, Nash M, Molaghan JB, et al. Oral dextran sulphate (UA001) in the treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Ann Intern Med 1989; 110: 183-8.
65. Pluda JM, Shay LE, Foli A, Tannenbaum S, Cohen PJ, Goldspiel BR, et al. Administration of pentosan polysulphate to patients with human immunodeficiency virus-associated Kaposi's sarcoma. J Natl Cancer Inst 1993; 85: 1585-92.
66. Marshall JL, Wellstein A, Rae J, DeLap RJ, Phipps K, Hanfelt J, et al. Phase I trial of orally administered pentosan polysulphate in patients with advanced cancer. Clin Cancer Res 1997; 3: 2347-54.
67. Swain SM, Parker B, Wellstein A, Lippman ME, Steakley C, DeLap R. Phase I trial of pentosan polysulphate. Invest New Drugs 1995; 13: 55-62.
68. Schwartsmann G, Sprinz E, Kalakun L, Yamagushi N, Sander E, Grivicich I, et al. Phase II study of pentosan polysulphate (PPS) in patients with AIDS-related Kaposi's sarcoma. Tumouri 1996; 82: 360-3.
69. Flexner C, Barditch-Crovo PA, Kornhauser DM, Farzadegan H, Nerhood LJ, Chaisson RE, et al. Pharmacokinetics, toxicity, and activity of intravenous dextran sulphate in human immunodeficiency virus infection. Antimicrob Agents Chemother 1991; 35: 2544-50.
70. Booth W. An underground drug for AIDS. Science 1988; 241: 1279-81.
71. Finco O, Nuti S, De Magistris MT, Mangiavacchi L, Aiuti A, Forte P, et al. Induction of CD4+ T cell depletion in mice doubly transgenic for HIV gp120 and human CD4. Eur J Immunol 1997; 27: 1319-24.
72. Corasaniti MT, Maccarrone M, Nistico R, Malorni W, Rotiroti D, Bagetta G. Exploitation of the HIV-1 coat glycoprotein, gp120, in neurodegenerative studies in vivo. J Neurochem 2001; 79: 1-8.
73. Two C, Liu NQ, Popik W, Bukrinsky M, Sayre J, Roberts J, et al. Cardiomyocytes undergo apoptosis in human immunodeficiency virus cardiomyopathy through mitochondrion- and death receptor-controlled pathways. Proc Natl Acad Sci USA 2002; 99: 14386-91.
74. Fakruddin JM, Laurence J. HIV envelope gp120-mediated regulation of osteoclastogenesis via RANKL secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk. J Biol Chem 2003.
75. Cioni C, Annunziata P. Circulating gp120 alters the blood-brain barrier permeability in HIV-1 gp120 transgenic mice. Neurosci Lett 2002; 330: 299-301.
76. Bragardo M, Buonfiglio D, Feito MJ, Bonissoni S, Redoglia V, Rojo JM, et al. Modulation of lymphocyte interaction with endothelium and homing by HIV-1 gp120. J Immunol 1997; 159: 1619-27.
77. Noonan D, Albini A. From the outside in: extracellular activities of HIV Tat. Adv Pharmacol 2000; 48: 229-50.
78. Rusnati M, Presta M. HIV-1 Tat protein and endothelium from protein/cell interaction to AIDS-associated pathologies. Angiogenesis 2002; 5: 141-51.
79. Rusnati M, Presta M. HIV-1 Tat protein: a target for the development of anti-AIDS therapies. Drug Fut 2002; 27: 481-93.
80. Goldstein G. HIV-1 Tat protein as a potential AIDS vaccine. Nat Med 1996; 2: 960-4.
81. Rusnati M, Tulipano G, Urbinati C, Langhetti E, Giuliani R, Giacca M, et al. The basic domain in HIV-1 Tat protein as a target for polysulfonated heparin-mimicking extracellular Tat antagonists. J Biol Chem 1998; 273: 16027-37.
82. Luscher-Mattli M. Polyanions--a lost chance in the fight against HIV and other virus diseases? Antivir Chem Chemother 2000; 11: 249-59.
83. Lorentsen KJ, Hendrix CW, Collins JM, Kornhauser DM, Petty BG, Klecker RW, et al. Dextran sulphate is poorly absorbed after oral administration. Ann Intern Med 1989; 111: 561-6.
84. Turpin JA. Considerations and development of topical microbicides to inhibit the sexual transmission of HIV. Expert Opin Investig Drugs 2002; 11: 1077-97.
85. Low-Beer N, Gabe R, McCormack S, Kitchen VS, Lacey CJ, Nunn AJ. Dextrin sulphate as a vaginal microbicide: randomised, double-blind, placebo-controlled trial including healthy female volunteers and their male partners. J Acquir Immune Defic Syndr 2002; 31: 391-8.
86. Maguire RA, Zacharopoulos VR, Phillips DM. Carrageenan-based nonoxynol-9 spermicides for preventior of sexually transmitted infections. Sex Transm Dis 1998; 25: 494-500.
87. Piret J, Lamontagne J, Bestman-Smith J, Roy S, Gourde P, Desormeaux A, et al. In vitro and in vivo evaluations of sodium lauryl sulphate and dextran sulphate as microbicides against herpes simplex and human immunodeficiency viruses. J Clin Microbiol 2000; 38: 110-9.
88. Ensoli B, Gendelman R, Markham P, Fiorelli V, Colombini S, Raffeld M, et al. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature 1994; 371: 674-80.
89. Li JP, Gong F, El Darwish K, Jalkanen M, Lindahl U. Characterisation of the D-glucuronyl C5-epimerase involved in the biosynthesis of heparin and heparan sulphate. J Biol Chem 2001; 276: 20069-77.
90. Li J, Hagner-McWhirter A, Kjellen L, Palgi J, Jalkanen M, Lindahl U. Biosynthesis of heparin/heparan sulphate. cDNA cloning and expression of D-glucuronyl C5-epimerase from bovine lung. J Biol Chem 1997; 272: 28159-63.
91. Avci FY, Karst NA, Linhardt RJ. Synthetic oligosaccharides as heparin-mimetics displaying anticoagulant properties. Curr Pharm Design 2003; 9(28): 2323-35.
92. Gruber A, Hanson SR. Potential new targets for antithrombotic therapy. Curr Pharm Design 2003; 9(28): 2367-74.
93. Presta M, Leali D, Stabile H, Ronca R, Camozzi M, Coco L, et al. Heparin derivatives as angiogenesis inhibitors. Curr Pharm Design 2003; 9(7): 553-66.